News - 27 Aug 2008
Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug...
News - 28 Mar 2012
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years...
News - 5 Jun 2006
Children with a rare digestive-tract cancer that is resistant to front-line therapy have benefited from a newer targeted therapy that has been shown effective in adults, according to data from a small...
News - 9 Jun 2004
A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).
News - 28 Sep 2020
Because gastrointestinal stromal tumors (GIST) are sensitive to the targeted small molecule therapy imatinib, oncologists tend to treat all patients with metastatic GIST with this drug. However,...
News - 18 Aug 2017
Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel,...
News - 17 Feb 2017
Many who have a chronic traumatic brain injury (TBI) report struggling to solve problems, understand complex information and maintain friendships, despite scoring normally on cognitive tests.
News - 17 Aug 2016
GIST (Gastrointestinal Stromal Tumor) is an uncommon type of sarcoma found in the tissues supporting the digestive system (stomach and intestines).
News - 14 Jun 2016
New research from the Center for BrainHealth at The University of Texas at Dallas shows that strategy-based reasoning training can improve the cognitive performance for those with mild cognitive...
News - 11 Jun 2013
ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.